SEC Company Response from Tonix Pharmaceuticals Holding Corp. (TNXP) (CIK 0001430306) (TNXP) — Jan 6, 2014
Tonix Pharmaceuticals Holding Corp. (TNXP) (CIK 0001430306)
Date: Jan. 6, 2014 · CIK: 0001430306 · Accession: 0001144204-14-000674
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-192541
Letter
Tonix Pharmaceuticals Holding Corp.
509 Madison Avenue, Suite 306
New York, New York 10022
January 6, 2014
VIA EDGAR
United States Securities
and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Erin Wilson, Esq.
Re: Tonix Pharmaceuticals Holding Corp.
Registration Statement on Form S-3
File No. 333-192541
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended (the “Act”), Tonix Pharmaceuticals Holding Corp. (the “Company”) respectfully requests that the effective date of the registration statement referred to above be accelerated so that it will become effective at 9:00 a.m., Eastern Standard Time, on Wednesday, January 8, 2014, or as soon thereafter as possible. The Company acknowledges that: 1) should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing; 2) the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and 3) the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
TONIX PHARMACEUTICALS HOLDING CORP.
By: /s/ SETH LEDERMAN
Name: Seth Lederman
Title: Chief Executive Officer
Show Raw Text
CORRESP
1
filename1.htm
Tonix Pharmaceuticals Holding Corp.
509 Madison Avenue, Suite 306
New York, New York 10022
January 6, 2014
VIA EDGAR
United States Securities
and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Erin Wilson, Esq.
Re: Tonix Pharmaceuticals Holding Corp.
Registration Statement on Form
S-3
File No. 333-192541
Ladies and Gentlemen:
Pursuant to Rule 461
of the General Rules and Regulations under the Securities Act of 1933, as amended (the “Act”), Tonix Pharmaceuticals
Holding Corp. (the “Company”) respectfully requests that the effective date of the registration statement referred
to above be accelerated so that it will become effective at 9:00 a.m., Eastern Standard Time, on Wednesday, January 8, 2014, or
as soon thereafter as possible. The Company acknowledges that: 1) should the Commission or the staff, acting pursuant to delegated
authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
2) the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not
relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and 3) the Company
may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or
any person under the federal securities laws of the United States.
TONIX PHARMACEUTICALS HOLDING CORP.
By: /s/ SETH LEDERMAN
Name: Seth Lederman
Title: Chief Executive Officer